Zenas BioPharma
ZBIO
139 hedge funds and large institutions have $1.1B invested in Zenas BioPharma in 2026 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 57 increasing their positions, 17 reducing their positions, and 27 closing their positions.
235% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 17
89% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 27
29% more call options, than puts
Call options by funds: $3.48M | Put options by funds: $2.71M
19.13% more ownership
Funds ownership: 77.43% → 96.56% (+19%)
18% more funds holding
Funds holding: 118 → 139 (+21)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
27% less capital invested
Capital invested by funds: $1.5B → $1.1B (-$407M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$54.6M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$33.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.9M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$25.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$23.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$52.6M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$31M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.21M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$5.95M |
| 5 |
EP
Eversept Partners
New York
|
-$4.39M |
ZBIO Hedge Fund Activity: Q1 2026 in Review
139 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Zenas BioPharma (ZBIO) for Q1 2026, worth a combined $1.1B — down 27% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new ZBIO positions and 27 closed out — a net gain of 24 holders — while 57 added to existing stakes and 17 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $54.6M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $52.6M sold.
- 139 institutional investors held Zenas BioPharma (ZBIO) as of Q1 2026, up from 118 in Q4 2025.
- Funds reported $1.1B of Zenas BioPharma stock for Q1 2026, down 27% quarter-over-quarter.
- 51 funds opened new Zenas BioPharma positions in Q1 2026 and 27 closed out, a net change of +24 holders.
- The largest Zenas BioPharma buyer in Q1 2026 was Capital International Investors, an estimated $54.6M added.
- The largest Zenas BioPharma seller in Q1 2026 was Novo Holdings A/S, an estimated $52.6M sold.
Based on aggregated 13F filings for Q1 2026.